Grundläggande statistik
| CIK | 1532079 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Cynapsus Therapeutics Inc.
SEC Filings (Chronological Order)
Denna sida innehåller en komplett, kronologisk lista över SEC-arkiveringar, exklusive ägande-arkiveringar som vi tillhandahåller på andra ställen.
| February 15, 2017 |
CYNA / Cynapsus Therapeutics Inc. / Visium Asset Management, LP - AMENDED SC 13G Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Cynapsus Therapeutics Inc. (Name of Issuer) Common Stock, no par value per share (Title of Class of Securities) 23257Y859 (CUSIP Number) December 31, 2017 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant |
|
| February 3, 2017 |
CYNA / Cynapsus Therapeutics Inc. / AISLING CAPITAL III LP - AMENDMENT NO. 2 Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Sunovion CNS Development Canada ULC (Name of Issuer) Common Stock, no par value (Title of Class of Securities) 23257Y859 (CUSIP Number) December 31, 2016 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the r |
|
| December 8, 2016 |
CYNA / Cynapsus Therapeutics Inc. / ORBIMED ADVISORS LLC - AMENDMENT NO. 4 Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| December 8, 2016 |
CUSIP No. 23257Y859 SCHEDULE 13G Page 1 of 1 Pages EXHIBIT A JOINT FILING AGREEMENT The undersigned hereby agree that the Statement on this Schedule 13G dated December 8, 2016 (the “Schedule 13G”), with respect to the Common Stock of Sunovion CNS Development Canada ULC (successor by amalgamation to Cynapsus Therapeutics Inc.) is filed on behalf of each of us pursuant to and in accordance with the |
|
| November 1, 2016 |
OMB APPROVAL OMB Number: 3235-0167 Expires: March 31, 2018 Estimated average burden hours per response 1. |
|
| October 24, 2016 |
CERTIFIED COPY Of a Document filed with the Province of British Columbia Registrar of Companies Exhibit 3.2 Mailing Address: PO Box 9431 Stn Prov Govt Victoria BC V8W 9V3 www.corporateonline.gov.bc.ca Location: 2nd Floor - 940 Blanshard Street Victoria BC 1 877 526-1526 CERTIFIED COPY Of a Document filed with the Province of British Columbia Registrar of Companies Notice of Articles BUSINESS CORPORATIONS ACT CAROL PREST This Notice of Articles was issued by the Registrar on: October 21, 2016 |
|
| October 24, 2016 |
Exhibit 3.1 Number: BC1093941 CERTIFICATE OF AMALGAMATION BUSINESS CORPORATIONS ACT I Hereby Certify that CYNAPSUS THERAPEUTICS INC., incorporation number C1093896, and PROJECT PEGASUS SUB ACQUISITION ULC, incorporation number BC1091512, and SUNOVION CNS DEVELOPMENT CANADA ULC, incorporation number BC1087995 were amalgamated as one company under the name SUNOVION CNS DEVELOPMENT CANADA ULC on Octo |
|
| October 24, 2016 |
8-K 1 v4510938k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 21, 2016 SUNOVION CNS DEVELOPMENT CANADA ULC (Exact name of registrant as specified in its charter) Canada 001-37426 98-1226819 (State or other ju |
|
| October 21, 2016 |
Notice of Articles BUSINESS CORPORATIONS ACT CERTIFIED COPY Of a Document filed with the Province of British Columbia Registrar of Companies CAROL PREST Notice of Articles BUSINESS CORPORATIONS ACT This Notice of Articles was issued by the Registrar on: October 21, 2016 10:19 AM Pacific Time Incorporation Number: C1093896 Recognition Date and Time: Continued into British Columbia on October 21, 2016 10:19 AM Pacific Time NOTICE OF ARTICLES Name of Company: CYNAPSUS THERAPEUTICS INC. |
|
| October 21, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 20, 2016 Cynapsus Therapeutics Inc. (Exact name of registrant as specified in its charter) Canada 001-37426 98-1226819 (State or other jurisdiction of incorporation) (Commissi |
|
| October 21, 2016 |
Exhibit 99.1 Sunovion Pharmaceuticals Inc. 84 Waterford Drive, Marlborough, MA 01752-7010 Tel 508-481-6700 Contacts: Patrick Gaffey Executive Director, Corporate Communications Sunovion Pharmaceuticals Inc. 508-787-4565 [email protected] Jennifer Baird Senior Director, Corporate Communications Sunovion Pharmaceuticals Inc. 508-787-4109 [email protected] Sunovion Pharmaceuticals |
|
| October 21, 2016 |
incorporation agreement Sunovion CNS Development Canada ULC (the “Company”) Exhibit 3.5 incorporation agreement Sunovion CNS Development Canada ULC (the ?Company?) I propose to form the Company under the Business Corporations Act (British Columbia). I agree to take the number and class of shares in the Company set opposite my name: Signature and full name of the Incorporator Date of signing Number and class of shares being taken by Incorporator Sunovion Pharmaceuticals In |
|
| October 21, 2016 |
Canada Business Corporations Act (CBCA) FORM 14.1 ARTICLES OF ARRANGEMENT (Section 192) Exhibit 3.1 Certificate of Arrangement Certificat d’arrangement Canada Business Corporation Act Loi canadienne sur les sociétés par actions Cynapsus Therapeutics Inc. 955505-6 Corporate name(s) of CBCA applicants / Dénomination(s) sociales(s) de la ou des sociétés LCSA requérantes Corporation number(s) / Numéro(s) de la ou des sociétés I HEREBY CERTIFY that the arrangement set out in the attached |
|
| October 21, 2016 |
CERTIFICATE BUSINESS CORPORATIONS ACT Exhibit 3.2 Number: C1093896 CERTIFICATE OF CONTINUATION BUSINESS CORPORATIONS ACT I Hereby Certify that Cynapsus Therapeutics Inc., has continued into British Columbia from the Jurisdiction of CANADA, under the Business Corporations Act, with the name CYNAPSUS THERAPEUTICS INC. on October 21, 2016 at 10:19 AM Pacific Time. Issued under my hand at Victoria, British Columbia On October 21, 2016 CAR |
|
| October 21, 2016 |
CYNAPSUS THERAPEUTICS INC. (the “Company”) Exhibit 3.4 ARTICLES CYNAPSUS THERAPEUTICS INC. (the ?Company?) The Company will have as its Articles on continuation the following Articles. Full name and signature of one of the directors pursuant to s.302(c) of the Business Corporations Act Date of signing Gregory M. Bokar Print Name /s/Gregory M. Bokar Signature October 21, 2016 Incorporation number: C1093896 CYNAPSUS THERAPEUTICS INC. (the ?C |
|
| October 21, 2016 |
S-8 POS 1 v450905s8pos.htm S-8 POS As filed with the Securities and Exchange Commission on October 21, 2016. Registration No. 333-205929 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-205929 CYNAPSUS THERAPEUTICS INC. (Exact name of registrant as specified in its charter) Canada 98-1226819 (State or |
|
| October 21, 2016 |
CYNA / Cynapsus Therapeutics Inc. / Sunovion Pharmaceuticals Inc. - SC 13D/A Activist Investment CUSIP No. 23257Y859 Page 1 of 5 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) Under the Securities Exchange Act of 1934 (Amendment No. 1)* CYNAPSUS THERAPEUTICS INC. (Name of Issuer) Common Shares, no par value (Ti |
|
| October 18, 2016 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 18, 2016 Cynapsus Therapeutics Inc. (Exact name of registrant as specified in its charter) Canada 001-37426 98-1226819 (State or other jurisdiction of incorporation) (Commissi |
|
| October 18, 2016 |
Exhibit 99.1 Cynapsus Therapeutics Obtains Final Court Order and HSR Waiting Period Expires for Plan of Arrangement with Sunovion Pharmaceuticals TORONTO - October 18, 2016 ? Cynapsus Therapeutics Inc. (?Cynapsus?) (NASDAQ:CYNA) (TSX: CTH), a specialty central nervous system pharmaceutical company developing a fast-acting, easy-to-use, sublingual thin film for the on-demand management of debilitat |
|
| October 13, 2016 |
Financial Statements and Exhibits, Other Events, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 13, 2016 Cynapsus Therapeutics Inc. (Exact name of registrant as specified in its charter) Canada 001-37426 98-1226819 (State or other jurisdiction of incorporation) (Commissi |
|
| October 13, 2016 |
Cynapsus Therapeutics Securityholders Approve the Plan of Arrangement with Sunovion Pharmaceuticals Exhibit 99.1 Cynapsus Therapeutics Securityholders Approve the Plan of Arrangement with Sunovion Pharmaceuticals TORONTO - October 13, 2016 – Cynapsus Therapeutics Inc. (“Cynapsus”) (NASDAQ:CYNA) (TSX: CTH), a specialty central nervous system pharmaceutical company developing a fast-acting, easy-to-use, sublingual thin film for the on-demand management of debilitating OFF episodes associated with |
|
| October 11, 2016 |
Unregistered Sales of Equity Securities UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 4, 2016 Cynapsus Therapeutics Inc. (Exact name of registrant as specified in its charter) Canada 001-37426 98-1226819 (State or other jurisdiction of incorporation) (Commissio |
|
| October 11, 2016 |
CYNA / Cynapsus Therapeutics Inc. / FRANKLIN RESOURCES INC Passive Investment cyna16a2.htm - Generated by SEC Publisher for SEC Filing CUSIP NO. 23257Y859 13G Page 1 of 12 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* CYNAPSUS THERAPEUTICS INC. (Name of Issuer) Common Shares, no par value (Title of Class of Securities) 23257Y859 (CUSIP Number) September 30, 2016 (Date of Even |
|
| September 29, 2016 |
ISS RECOMMENDS CYNAPSUS THERAPEUTICS SECURITYHOLDERS VOTE FOR THE PLAN OF ARRANGEMENT Exhibit 99.1 ISS RECOMMENDS CYNAPSUS THERAPEUTICS SECURITYHOLDERS VOTE FOR THE PLAN OF ARRANGEMENT TORONTO ? September 28, 2016 ? Cynapsus Therapeutics Inc. (?Cynapsus?) (NASDAQ:CYNA) (TSX: CTH) is pleased to announce today that Institutional Shareholder Services (?ISS?), a leading independent proxy advisory firm, has recommended that Cynapsus shareholders and warrantholders (together, ?Securityho |
|
| September 29, 2016 |
Regulation FD Disclosure, Financial Statements and Exhibits 8-K 1 v4496468k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 28, 2016 Cynapsus Therapeutics Inc. (Exact name of registrant as specified in its charter) Canada 001-37426 98-1226819 (State or other jurisdict |
|
| September 19, 2016 |
Unregistered Sales of Equity Securities UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 13, 2016 Cynapsus Therapeutics Inc. (Exact name of registrant as specified in its charter) Canada 001-37426 98-1226819 (State or other jurisdiction of incorporation) (Commis |
|
| September 16, 2016 |
Exhibit 99.2 The instructions accompanying this Letter of Transmittal should be read carefully before completing this Letter of Transmittal. TSX Trust Company (the ?Depository?) or your broker or other financial advisor will assist you in completing this Letter of Transmittal. This Letter of Transmittal is for use only by registered shareholders or warrantholders of Cynapsus Therapeutics Inc. (the |
|
| September 16, 2016 |
Exhibit 99.3 Cynapsus Therapeutics Inc. (the ?Corporation?) FORM OF PROXY (?PROXY?) Common Shareholders Special Meeting October 13, 2016 at 10 a.m. (Toronto Time) Borden Ladner Gervais LLP, Scotia Plaza 40 King Street West, Suite 4400 Toronto, Ontario, Canada, M5H 3Y4 (the ?Meeting?) RECORD DATE: September 9, 2016 CONTROL NUMBER: SEQUENCE #: FILING DEADLINE FOR PROXY: October 11, 2016 at 10 a.m. ( |
|
| September 16, 2016 |
Exhibit 99.4 Cynapsus Therapeutics Inc. (the ?Corporation?) FORM OF PROXY (?PROXY?) Warrantholders Special Meeting October 13, 2016 at 10 a.m. (Toronto Time) Borden Ladner Gervais LLP, Scotia Plaza 40 King Street West, Suite 4400 Toronto, Ontario, Canada, M5H 3Y4 (the ?Meeting?) RECORD DATE: September 9, 2016 CONTROL NUMBER: SEQUENCE #: FILING DEADLINE FOR PROXY: October 11, 2016 at 10 a.m. (Toron |
|
| September 16, 2016 |
Exhibit 99.1 This document is important and requires your immediate attention. If you are in any doubt as to how to deal with it, you should consult your financial, legal or other professional advisor. This document does not constitute an offer or a solicitation to any person in any jurisdiction in which such offer or solicitation is unlawful. If you have questions, you may contact Cynapsus? proxy |
|
| September 16, 2016 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 16, 2016 Cynapsus Therapeutics Inc. (Exact name of registrant as specified in its charter) Canada 001-37426 98-1226819 (State or other jurisdiction of incorporation) (Commis |
|
| September 16, 2016 |
CYNA / Cynapsus Therapeutics Inc. / ORBIMED ADVISORS LLC - AMENDMENT NO. 3 Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| September 16, 2016 |
CUSIP No. 23257Y859 SCHEDULE 13G Page 1 of 1 Pages EXHIBIT A JOINT FILING AGREEMENT The undersigned hereby agree that the Statement on this Schedule 13G dated September 16, 2016 (the “Schedule 13G”), with respect to the Common Stock of Cynapsus Therapeutics Inc. is filed on behalf of each of us pursuant to and in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of |
|
| September 15, 2016 |
EX-99.3 Exhibit 3 Execution Copy VOTING AND SUPPORT AGREEMENT THIS AGREEMENT made the 31st day of August, 2016 BETWEEN: SUNOVION CNS DEVELOPMENT CANADA ULC, a corporation governed by the laws of British Columbia; (the “Purchaser”) - and - DEXXON HOLDINGS LTD. (the “Shareholder”) WHEREAS: 1. The Purchaser intends to acquire all of the outstanding common shares (the “Common Shares”) and Common Share |
|
| September 15, 2016 |
EX-99.2 Exhibit 2 Execution Copy VOTING AND SUPPORT AGREEMENT THIS AGREEMENT made the 31st day of August, 2016 BETWEEN: SUNOVION CNS DEVELOPMENT CANADA ULC, a corporation governed by the laws of British Columbia; (the “Purchaser”) - and - DEXCEL PHARMA TECHNOLOGIES LTD. (the “Shareholder”) WHEREAS: 1. The Purchaser intends to acquire all of the outstanding common shares (the “Common Shares”) and C |
|
| September 15, 2016 |
CYNA / Cynapsus Therapeutics Inc. / Dexxon Holdings Ltd. - SC 13D/A Activist Investment SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. |
|
| September 12, 2016 |
CYNA / Cynapsus Therapeutics Inc. / Sunovion Pharmaceuticals Inc. - SC 13D Activist Investment CUSIP No. 741865 109 Page 1 of 9 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 CYNAPSUS THERAPEUTICS INC. (Name of Issuer) Common Shares, no par value (Title of Class of Securities) 23257Y859 (CUSIP Number) Sunovion Pharmaceuticals Inc. 84 Waterford Drive Marlborough, Massachusetts 01752 508-481-6700 (Name, Address an |
|
| September 7, 2016 |
Unregistered Sales of Equity Securities UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 31, 2016 Cynapsus Therapeutics Inc. (Exact name of registrant as specified in its charter) Canada 001-37426 98-1226819 (State or other jurisdiction of incorporation) (Commissio |
|
| September 1, 2016 |
Exhibit 99.1 Sunovion Pharmaceuticals Inc. 84 Waterford Drive, Marlborough, MA 01752-7010 Tel 508-481-6700 Cynapsus Therapeutics Inc. 828 Richmond Street West, Toronto, ON, M6J 1C9 Tel 416-703-2449 Contacts: Pat |
|
| September 1, 2016 |
Cynapsus Therapeutics FORM 8-K (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 31, 2016 Cynapsus Therapeutics Inc. (Exact name of registrant as specified in its charter) Canada 001-37426 98-1226819 (State or other jurisdiction of incorporation) (Commissio |
|
| September 1, 2016 |
Exhibit 2.1 ARRANGEMENT AGREEMENT SUNOVION CNS DEVELOPMENT CANADA ULC - and - SUNOVION PHARMACEUTICALS INC. - and - CYNAPSUS THERAPEUTICS INC. August 31, 2016 TABLE OF CONTENTS Article 1 Interpretation 2 1.1 Definitions 2 1.2 Construction 17 1.3 Currency 18 1.4 Accounting Matters 18 1.5 Knowledge 18 1.6 Accounting Terms 18 1.7 Subsidiaries 19 1.8 Disclosure Letter 19 1.9 Schedules 19 Article 2 Arr |
|
| September 1, 2016 |
SHARE PURCHASE AGREEMENT AMENDING AGREEMENT Exhibit 2.2 SHARE PURCHASE AGREEMENT AMENDING AGREEMENT THIS AGREEMENT dated as of the 31st day of August, 2016. A M O N G: CYNAPSUS THERAPEUTICS INC. (hereinafter called the ?Purchaser?) OF THE FIRST PART - and - THE PERSONS SET OUT IN EXHIBIT ?A? HERETO (hereinafter collectively called the ?Shareholders?) OF THE SECOND PART WHEREAS the Purchaser and the Shareholders entered into a share purchase |
|
| September 1, 2016 |
Exhibit 10.1 VOTING AND SUPPORT AGREEMENT THIS AGREEMENT made as of the 31st day of August, 2016 BETWEEN: SUNOVION CNS DEVELOPMENT CANADA ULC, a corporation governed by the laws of British Columbia. (the ?Purchaser?) - and - [SHAREHOLDER] (the ?Shareholder?) WHEREAS: 1. The Purchaser intends to acquire all of the outstanding common shares (the ?Common Shares?) and Common Share purchase warrants (t |
|
| September 1, 2016 |
Exhibit 10.2 VOTING AND SUPPORT AGREEMENT THIS AGREEMENT made the 31st day of August, 2016 BETWEEN: SUNOVION CNS DEVELOPMENT CANADA ULC, a corporation governed by the laws of British Columbia. (the ?Purchaser?) - and - [SHAREHOLDER] (the ?Shareholder?) WHEREAS: 1. The Purchaser intends to acquire all of the outstanding common shares (the ?Common Shares?) and Common Share purchase warrants (the ?Wa |
|
| August 29, 2016 |
Other Events, Financial Statements and Exhibits 8-K 1 v4478518k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 29, 2016 Cynapsus Therapeutics Inc. (Exact name of registrant as specified in its charter) Canada 001-37426 98-1226819 (State or other jurisdiction |
|
| August 29, 2016 |
EX-99.1 2 v44785199-1.htm EXHIBIT 99.1 Exhibit 99.1 Cynapsus Receives FDA Fast Track Designation for APL-130277 for the Treatment of OFF Episodes in Patients with Parkinson’s Disease - Company provides timing updates - TORONTO – Aug. 29, 2016 – Cynapsus Therapeutics Inc. (NASDAQ: CYNA) (TSX: CTH), today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation f |
|
| August 15, 2016 |
COMMERCIAL SUPPLY AGREEMENT CYNAPSUS THERAPEUTICS INC. - and - ARx, LLC Dated as of August 9, 2016 Exhibit 10.1 CONFIDENTIAL TREATMENT HAS BEEN REQUESTED BY CYNAPSUS THERAPEUTICS INC. Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission. COMMERCIAL SUPPLY AGREEMENT CYNAPSUS |
|
| August 15, 2016 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits 8-K 1 v4469328k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 9, 2016 Cynapsus Therapeutics Inc. (Exact name of registrant as specified in its charter) Canada 001-37426 98-1226819 (State or other jurisdiction of in |
|
| August 15, 2016 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits 8-K 1 v4469328k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 9, 2016 Cynapsus Therapeutics Inc. (Exact name of registrant as specified in its charter) Canada 001-37426 98-1226819 (State or other jurisdiction of in |
|
| August 15, 2016 |
COMMERCIAL SUPPLY AGREEMENT CYNAPSUS THERAPEUTICS INC. - and - ARx, LLC Dated as of August 9, 2016 Exhibit 10.1 CONFIDENTIAL TREATMENT HAS BEEN REQUESTED BY CYNAPSUS THERAPEUTICS INC. Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission. COMMERCIAL SUPPLY AGREEMENT CYNAPSUS |
|
| August 15, 2016 |
Financial Statements and Exhibits, Other Events 8-K 1 v4469348k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 15, 2016 Cynapsus Therapeutics Inc. (Exact name of registrant as specified in its charter) Canada 001-37426 98-1226819 (State or other jurisdiction of i |
|
| August 15, 2016 |
Exhibit 99.1 Cynapsus Announces Positive Opinion from Data and Safety Monitoring Board on Phase 3 Parkinson?s Disease Clinical Study Allowing for At-Home Titration TORONTO ? Aug. 15, 2016 ? Cynapsus Therapeutics Inc. (NASDAQ: CYNA) (TSX: CTH), a specialty central nervous system (CNS) pharmaceutical company developing and preparing to commercialize a fast-acting, easy-to-use, sublingual thin film f |
|
| August 15, 2016 |
Financial Statements and Exhibits, Other Events 8-K 1 v4469348k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 15, 2016 Cynapsus Therapeutics Inc. (Exact name of registrant as specified in its charter) Canada 001-37426 98-1226819 (State or other jurisdiction of i |
|
| August 15, 2016 |
Exhibit 99.1 Cynapsus Announces Positive Opinion from Data and Safety Monitoring Board on Phase 3 Parkinson?s Disease Clinical Study Allowing for At-Home Titration TORONTO ? Aug. 15, 2016 ? Cynapsus Therapeutics Inc. (NASDAQ: CYNA) (TSX: CTH), a specialty central nervous system (CNS) pharmaceutical company developing and preparing to commercialize a fast-acting, easy-to-use, sublingual thin film f |
|
| August 10, 2016 |
Exhibit 99.1 Cynapsus Therapeutics Reports Second Quarter 2016 Financial Results and Recent Developments - Recent Positive Dose Titration Data from Pivotal Phase 3 Clinical Program - - On Track for New Drug Application Submission in the First Half of 2017 - TORONTO, Aug. 10, 2016 ? Cynapsus Therapeutics Inc. (NASDAQ: CYNA) (TSX: CTH), a specialty central nervous system pharmaceutical company devel |
|
| August 10, 2016 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 10, 2016 Cynapsus Therapeutics Inc. (Exact name of registrant as specified in its charter) Canada 001-37426 98-1226819 (State or other jurisdiction of incorporation) (Commissio |
|
| August 10, 2016 |
Cynapsus Therapeutics FORM 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2016 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37426 CYNAPSUS THER |
|
| July 19, 2016 |
Financial Statements and Exhibits, Other Events 8-K 1 v4443638k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 19, 2016 Cynapsus Therapeutics Inc. (Exact name of registrant as specified in its charter) Canada 001-37426 98-1226819 (State or other jurisdiction o |
|
| July 19, 2016 |
Exhibit 99.1 Developing a Sublingual Formulation of Apomorphine to Rapidly Convert Parkinson?s Patients from OFF to ON State Analyst & Investor Day New York, NY July 19, 2016 www.cynapsus.ca 2 Analyst & Investor Day July 19, 2016 Kristen Galfetti Vice President, Investor Relations Cynapsus Therapeutics 2 3 This presentation has been prepared by Cynapsus Therapeutics Inc . , ?Cynapsus? or the ?Comp |
|
| July 18, 2016 |
Financial Statements and Exhibits, Other Events 8-K 1 v4443328k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 18, 2016 Cynapsus Therapeutics Inc. (Exact name of registrant as specified in its charter) Canada 001-37426 98-1226819 (State or other jurisdiction o |
|
| July 18, 2016 |
EX-99.2 3 v444332ex99-2.htm EXHIBIT 99.2 Exhibit 99.2 Cynapsus Therapeutics Provides European Clinical Update for APL-130277 for the Treatment of OFF Episodes in Patients with Parkinson's Disease - Company plans to initiate pivotal program in fourth quarter – - Webcast with accompanying slides to discuss program tomorrow at 7:30 a.m. Eastern time - TORONTO – July 18, 2016 – Cynapsus Therapeutics I |
|
| July 18, 2016 |
EX-99.1 2 v444332ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Cynapsus Therapeutics Announces Positive Phase 3 Dose Titration Phase Results with APL-130277 for the Treatment of OFF Episodes in Patients with Parkinson's Disease - Webcast with accompanying slides to discuss these findings tomorrow at 7:30 a.m. Eastern time Top-line CTH-300 results expected in late Q3 or early Q4 - TORONTO – July 18, 2016 – |
|
| July 8, 2016 |
CUSIP No. 23257Y859 SCHEDULE 13G Page 1 of 1 Pages EXHIBIT A JOINT FILING AGREEMENT The undersigned hereby agree that the Statement on this Schedule 13G dated July 8, 2016 (the “Schedule 13G”), with respect to the Common Stock of Cynapsus Therapeutics Inc. is filed on behalf of each of us pursuant to and in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934, |
|
| July 8, 2016 |
CYNA / Cynapsus Therapeutics Inc. / ORBIMED ADVISORS LLC - AMENDMENT NO. 1 Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| June 30, 2016 |
Exhibit 99.1 Cynapsus Therapeutics Enrolls Last Patient in Pivotal Phase 3 Efficacy Trial of APL-130277 to Treat OFF Episodes in Patients with Parkinson’s Disease - Dose titration phase results expected in mid to late July with top-line results expected near the end of Q3 2016 - TORONTO – June 30, 2016 – Cynapsus Therapeutics Inc. (NASDAQ: CYNA) (TSX: CTH), a specialty central nervous system (CNS) |
|
| June 30, 2016 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 30, 2016 Cynapsus Therapeutics Inc. (Exact name of registrant as specified in its charter) Canada 001-37426 98-1226819 (State or other jurisdiction of incorporation) (Commission |
|
| June 21, 2016 |
Exhibit 99.1 Cynapsus Therapeutics Announces Data Presentations at the International Congress of Parkinson’s Disease and Movement Disorders - Presentations include results from physician, patient and caregiver primary research, positive preclinical toxicology results and physician OFF episode treatment practices - TORONTO – June 21, 2016 – Cynapsus Therapeutics Inc. (NASDAQ: CYNA) (TSX:CTH), a spe |
|
| June 21, 2016 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 21, 2016 Cynapsus Therapeutics Inc. (Exact name of registrant as specified in its charter) Canada 001-37426 98-1226819 (State or other jurisdiction of incorporation) (Commission |
|
| May 20, 2016 |
Cynapsus Therapeutics Appoints Frederick Driscoll to Its Board of Directors Exhibit 99.1 Cynapsus Therapeutics Appoints Frederick Driscoll to Its Board of Directors TORONTO, May 20, 2016 - Cynapsus Therapeutics Inc. (?Cynapsus? or the ?Company?) (NASDAQ:CYNA) (TSX:CTH), a specialty central nervous system (?CNS?) pharmaceutical company developing and preparing to commercialize a fast-acting, easy-to-use, sublingual thin film for the on-demand management of debilitating OFF |
|
| May 20, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 20, 2016 Cynapsus Therapeutics Inc. (Exact name of registrant as specified in its charter) Canada 001-37426 98-1226819 (State or other jurisdiction of incorporation) (Commission F |
|
| May 11, 2016 |
8-K 1 v4395138k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 10, 2016 Cynapsus Therapeutics Inc. (Exact name of registrant as specified in its charter) Canada 001-37426 98-1226819 (State or other jurisdiction of |
|
| May 11, 2016 |
Cynapsus Therapeutics Announces Results of AGM EX-99.1 4 v439513ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 PRESS RELEASE Cynapsus Therapeutics Announces Results of AGM TORONTO, May 11, 2016 – Cynapsus Therapeutics Inc. (NASDAQ: CYNA) (TSX: CTH) (“Cynapsus” or the “Company”), a specialty central nervous system pharmaceutical company developing and preparing to commercialize a fast-acting, easy-to-use, sublingual thin film for the on-demand management |
|
| May 11, 2016 |
EX-3.1 2 v439513ex3-1.htm EXHIBIT 3.1 Exhibit 3.1 BY-LAW NO. 4 A by-law relating generally to the transaction of the business and affairs of CYNAPSUS THERAPEUTICS INC. (hereinafter called the “Corporation”) CONTENTS 1. Interpretation 2. Business of the Corporation 3. Directors 4. Committees 5. Officers 6. Protection of Directors, Officers and Others 7. Shares 8. Dividends and Rights 9. Meetings of |
|
| May 11, 2016 |
EX-4.1 3 v439513ex4-1.htm EXHIBIT 4.1 Exhibit 4.1 STOCK OPTION PLAN, AS AMENDED 2016 AMENDED AND RESTATED STOCK OPTION PLAN CYNAPSUS THERAPEUTICS INC. (the “Corporation”) DIRECTORS, MANAGEMENT, EMPLOYEES AND CONSULTANTS STOCK OPTION PLAN ARTICLE 1 – INTRODUCTION 1.1 Purpose The purpose of the Plan is to secure for the Corporation and its shareholders the benefits of incentives inherent in share ow |
|
| May 11, 2016 |
Results of Operations and Financial Condition, Financial Statements and Exhibits 8-K 1 v4394878k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 11, 2016 Cynapsus Therapeutics Inc. (Exact name of registrant as specified in its charter) Canada 001-37426 98-1226819 (State or other jurisdiction of |
|
| May 11, 2016 |
EX-99.1 2 v439487ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 PRESS RELEASE Cynapsus Therapeutics Reports First Quarter 2016 Financial Results and Recent Developments - Focus on Advancement of Pivotal Phase 3 Clinical Program in 2016 - TORONTO, May 11, 2016 – Cynapsus Therapeutics Inc. (NASDAQ: CYNA) (TSX: CTH), a specialty central nervous system pharmaceutical company developing and preparing to commerci |
|
| May 11, 2016 |
Cynapsus Therapeutics FORM 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2016 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37426 CYNAPSUS THE |
|
| April 19, 2016 |
Exhibit 99.4 |
|
| April 19, 2016 |
Exhibit 99.1 CYNAPSUS THERAPEUTICS INC. Annual and Special Meeting of Shareholders And Management Information Circular April 4, 2016 CYNAPSUS THERAPEUTICS INC. NOTICE OF ANNUAL AND SPECIAL MEETING OF SHAREHOLDERS To the shareholders of Cynapsus Therapeutics Inc. (the ?Corporation?): NOTICE IS HEREBY GIVEN that the Annual and Special Meeting (the ?Meeting?) of the shareholders of Cynapsus Therapeut |
|
| April 19, 2016 |
Cynapsus Therapeutics FORM 8-K (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 19, 2016 Cynapsus Therapeutics Inc. (Exact name of registrant as specified in its charter) Canada 001-37426 98-1226819 (State or other jurisdiction of incorporation) (Commission |
|
| April 19, 2016 |
Exhibit 99.3 |
|
| April 19, 2016 |
Exhibit 99.2 |
|
| April 6, 2016 |
Cynapsus Therapeutics FORM 8-K (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 1, 2016 Cynapsus Therapeutics Inc. (Exact name of registrant as specified in its charter) Canada 001-37426 98-1226819 (State or other jurisdiction of incorporation) (Commission |
|
| April 6, 2016 |
Exhibit 10.1 Execution Copy CONFIDENTIAL TREATMENT HAS BEEN REQUESTED BY CYNAPSUS THERAPEUTICS INC. Portions herein identified by [**] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission. LICENSE AGREEMENT by and |
|
| April 6, 2016 |
Exhibit 99.1 Cynapsus Therapeutics and MonoSol Rx Announce Global IP Licensing Agreement - Strengthening Intellectual Property for Sublingual Delivery of Apomorphine to Treat OFF Episodes in Parkinson’s Disease Patients - TORONTO, NEW JERSEY, April 4, 2016 – Cynapsus Therapeutics Inc. (“Cynapsus” or the “Company”) (NASDAQ: CYNA) (TSX: CTH), and MonoSol Rx LLC (“MonoSol Rx”) today announced that th |
|
| March 18, 2016 |
Cynapsus Therapeutics FORM 10-K/A (Annual Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A Amendment No. 1 (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2015 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37426 |
|
| March 16, 2016 |
JOINT FILING AGREEMENT PURSUANT TO RULE 13d-1(k) EX-99.1 Exhibit 1 JOINT FILING AGREEMENT PURSUANT TO RULE 13d-1(k) The undersigned acknowledge and agree that the foregoing statement on Schedule 13D is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13D may be filed on behalf of each of the undersigned without the necessity of filing additional joint filing agreements. The undersigned a |
|
| March 16, 2016 |
CYNA / Cynapsus Therapeutics Inc. / Dexxon Holdings Ltd. - SC 13D Activist Investment SC 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240. |
|
| March 9, 2016 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 9, 2016 Cynapsus Therapeutics Inc. (Exact name of registrant as specified in its charter) Canada 001-37426 98-1226819 (State or other jurisdiction of incorporation) (Commission |
|
| March 9, 2016 |
Exhibit 99.1 Cynapsus Therapeutics Reports Financial Results for the Fourth Quarter and Year Ended 2015 - Focus on Advancement of Pivotal Phase 3 Clinical Program in 2016 - TORONTO, March 9, 2016 ? Cynapsus Therapeutics Inc. (NASDAQ: CYNA) (TSX: CTH), a specialty central nervous system pharmaceutical company developing and preparing to commercialize a fast-acting, easy-to-use, sublingual thin film |
|
| March 9, 2016 |
Cynapsus Therapeutics FORM 10-K (Annual Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2015 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37426 CYNAPSUS THERAPEU |
|
| March 9, 2016 |
Exhibit 16.1 March 9, 2016 United States Securities and Exchange Commission 100 F Street, N.E. Washington, DC 20549 Ladies and Gentlemen: We have read Item 9 of Cynapsus Therapeutics Inc.’s (the “Company”) Annual Report on Form 10-K for the year ended December 31, 2015, and are in agreement with the statements contained in the second and third sentences of the first paragraph, and the second, thir |
|
| March 9, 2016 |
Subsidiary of Cynapsus Therapeutics Inc. EX-21.1 3 v433521ex21-1.htm EXHIBIT 21.1 Exhibit 21.1 Subsidiary of Cynapsus Therapeutics Inc. Cynapsus Therapeutics (USA) Inc., a Delaware corporation |
|
| March 7, 2016 |
Cynapsus Therapeutics Provides Company Update at Cowen & Co. 36th Annual Health Care Conference Exhibit 99.1 Cynapsus Therapeutics Provides Company Update at Cowen & Co. 36th Annual Health Care Conference TORONTO, March 7, 2016 – Cynapsus Therapeutics Inc. (NASDAQ: CYNA) (TSX: CTH), a specialty central nervous system pharmaceutical company developing and preparing to commercialize a fast-acting, easy-to-use, sublingual thin film for the on-demand management of debilitating OFF episodes assoc |
|
| March 7, 2016 |
Cynapsus Therapeutics FORM 8-K (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 7, 2016 Cynapsus Therapeutics Inc. (Exact name of registrant as specified in its charter) Canada 001-37426 98-1226819 (State or other jurisdiction of incorporation) (Commission |
|
| February 22, 2016 |
Cynapsus Therapeutics SC 13G (Passive Acquisition of More Than 5% of Shares) SC 13G SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Cynapsus Therapeutics Inc. (Name of Issuer) Common Stock, no par value per share (Title of Class of Securities) 23257Y859 (CUSIP Number) February 11, 2016 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which thi |
|
| February 16, 2016 |
CYNA / Cynapsus Therapeutics Inc. / ORBIMED ADVISORS LLC - SCHEDULE 13G AMENDMENT Passive Investment SC 13G/A 1 cyna123115a1.htm SCHEDULE 13G AMENDMENT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Cynapsus Therapeutics Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 23257Y859 (CUSIP Number) December 31, 2015 (Date of Event Which Requires Filing of this Statement) Check the approp |
|
| February 5, 2016 |
CYNA / Cynapsus Therapeutics Inc. / AISLING CAPITAL III LP - AMENDMENT NO. 1 Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Cynapsus Therapeutics Inc. (Name of Issuer) Common Stock, no par value (Title of Class of Securities) 23257Y859 (CUSIP Number) December 31, 2015 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursu |
|
| February 4, 2016 |
CYNA / Cynapsus Therapeutics Inc. / FRANKLIN RESOURCES INC Passive Investment cyna15a1.htm - Generated by SEC Publisher for SEC Filing CUSIP NO. 23257Y859 13G Page 1 of 15 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* CYNAPSUS THERAPEUTICS INC. (Name of Issuer) Common Share, no par value (Title of Class of Securities) 23257Y859 (CUSIP Number) December 31, 2015 (Date of Event |
|
| February 3, 2016 |
Exhibit 10.1 THIS LEASE made the 1st day of February, 2016. BETWEEN: RICHMOND WALNUT BUSINESS CENTRE INC. a Corporation Incorporated under the laws of the Province of Ontario (hereinafter called the ?Landlord?) -and- CYNAPSUS THERAPEUTICS INC. a Corporation Incorporated under the laws of the Province of Ontario. (hereinafter called the ?Tenant?) WITNESSETH that in consideration of the rents hereby |
|
| February 3, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 1, 2016 Cynapsus Therapeutics Inc. (Exact name of registrant as specified in its charter) Canada 001-37426 98-1226819 (State or other jurisdiction of incorporation) (Commissi |
|
| January 7, 2016 |
Cynapsus Therapeutics FORM 8-K (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 7, 2016 Cynapsus Therapeutics Inc. (Exact name of registrant as specified in its charter) Canada 001-37426 98-1226819 (State or other jurisdiction of incorporation) (Commissio |
|
| January 7, 2016 |
Exhibit 99.1 PRESS RELEASE Cynapsus and Michael J. Fox Foundation Collaborate on Pilot Use of Wearable Device and Data Science Approaches in Phase 3 Parkinson’s Clinical Study Pivotal trial of Cynapsus’ under-the-tongue apomorphine formulation will include technology-enabled sub-study to gather and analyze objective patient data on disease progression and medication effect Effort builds on ongoing |
|
| January 4, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 1, 2016 Cynapsus Therapeutics Inc. (Exact name of registrant as specified in its charter) Canada 001-37426 98-1226819 (State or other jurisdiction of incorporation) (Commissio |
|
| January 4, 2016 |
Exhibit 3.1 |
|
| January 4, 2016 |
Cynapsus Therapeutics Completes Short-Form Amalgamation with Wholly-Owned Subsidiary Exhibit 99.1 PRESS RELEASE Cynapsus Therapeutics Completes Short-Form Amalgamation with Wholly-Owned Subsidiary January 4, 2016 TORONTO ? Cynapsus Therapeutics Inc. (?Cynapsus? or the ?Company?) (NASDAQ: CYNA) (TSX: CTH), a specialty central nervous system (?CNS?) pharmaceutical company developing and preparing to commercialize a fast-acting, easy-to-use, sublingual thin film for the on-demand man |
|
| December 15, 2015 |
Cynapsus Therapeutics 8-K (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 15, 2015 Cynapsus Therapeutics Inc. (Exact name of registrant as specified in its charter) Canada 001-37426 98-1226819 (State or other jurisdiction of incorporation) (Commiss |
|
| December 14, 2015 |
Cynapsus Therapeutics FORM 144 UNITED STATES OMB APPROVAL SECURITIES AND EXCHANGE COMMISSION OMB Number: 3235-0101 Washington, D. |
|
| December 10, 2015 |
Cynapsus Therapeutics FORM 8-K (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 10, 2015 Cynapsus Therapeutics Inc. (Exact name of registrant as specified in its charter) Canada 001-37426 98-1226819 (State or other jurisdiction of incorporation) (Commiss |
|
| December 10, 2015 |
Exhibit 99.1 PRESS RELEASE Cynapsus Therapeutics Announces Successful Completion of Bioavailability and Pharmacokinetic Study and Provides Update on European Clinical Plans December 10, 2015 TORONTO ? Cynapsus Therapeutics Inc. (NASDAQ: CYNA) (TSX: CTH), a specialty central nervous system (?CNS?) pharmaceutical company developing and preparing to commercialize a fast-acting, easy-to-use, sublingua |
|
| November 25, 2015 |
Cynapsus Therapeutics FORM 144 Form 144 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 OMB APPROVAL OMB Number: 3235-0101 Expires: May 7 2017 Estimated average burden hours per response 1.00 FORM 144 SEC USE ONLY NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933 DOCUMENT SEQUENCE NO. ATTENTION: Transmit for filing 3 copies of this form concurrently with either p |
|
| November 25, 2015 |
Cynapsus Therapeutics FORM 144/A Form 144 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 OMB APPROVAL OMB Number: 3235-0101 Expires: May 7 2017 Estimated average burden hours per response 1.00 FORM 144/A (Amendment No. 1) SEC USE ONLY NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933 DOCUMENT SEQUENCE NO. ATTENTION: Transmit for filing 3 copies of this form concur |
|
| November 12, 2015 |
Cynapsus Therapeutics FORM 8-K (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 12, 2015 Cynapsus Therapeutics Inc. (Exact name of registrant as specified in its charter) Canada 001-37426 98-1226819 (State or other jurisdiction of incorporation) (Commiss |
|
| November 12, 2015 |
Cynapsus Therapeutics Reports Third Quarter 2015 Financial Results and Recent Developments Exhibit 99.1 PRESS RELEASE Cynapsus Therapeutics Reports Third Quarter 2015 Financial Results and Recent Developments November 12, 2015 TORONTO ? Cynapsus Therapeutics Inc. (NASDAQ: CYNA) (TSX: CTH) (?Cynapsus? or the ?Company?), a specialty central nervous system (?CNS?) pharmaceutical company developing and preparing to commercialize a fast-acting, easy-to-use, sublingual thin film for the on-de |
|
| October 9, 2015 |
CYNA / Cynapsus Therapeutics Inc. / FRANKLIN RESOURCES INC Passive Investment cyna15in.htm - Generated by SEC Publisher for SEC Filing CUSIP NO. 23257Y859 13G Page 1 of 14 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* CYNAPSUS THERAPEUTICS INC. (Name of Issuer) Common Shares, no par value (Title of Class of Securities) 23257Y859 (CUSIP Number) September 30, 2015 (Date of Event |
|
| October 2, 2015 |
EX-10.2 3 v421498ex10-2.htm EXHIBIT 10.2 Exhibit 10.2 EMPLOYMENT AGREEMENT THIS AGREEMENT made as of the 1st day of October, 2015. BETWEEN: CYNAPSUS THERAPEUTICS INC. (hereinafter called “Cynapsus”) - and - ANDREW WILLIAMS (hereinafter called the “Executive”) WHEREAS Cynapsus is developing a sublingual thin filmstrip for the acute rescue of OFF motor symptoms of Parkinson’s disease; AND WHEREAS Cy |
|
| October 2, 2015 |
Exhibit 10.1 EMPLOYMENT AGREEMENT THIS AGREEMENT made as of the 1st day of October, 2015. BETWEEN: CYNAPSUS THERAPEUTICS INC. (hereinafter called ?Cynapsus?) - and - ANTHONY GIOVINAZZO (hereinafter called the ?Executive?) WHEREAS Cynapsus is developing a sublingual thin filmstrip for the acute rescue of OFF motor symptoms of Parkinson?s disease; AND WHEREAS Cynapsus and the Executive entered into |
|
| October 2, 2015 |
Exhibit 10.4 EMPLOYMENT AGREEMENT THIS AGREEMENT made as of the 1st day of October, 2015. BETWEEN: CYNAPSUS THERAPEUTICS INC. (hereinafter called ?Cynapsus?) - and - Albert Agro (hereinafter called the ?Executive?) WHEREAS Cynapsus is developing a sublingual thin filmstrip for the acute rescue of OFF motor symptoms of Parkinson?s disease; AND WHEREAS Cynapsus and the Executive entered into an orig |
|
| October 2, 2015 |
Exhibit 10.3 EMPLOYMENT AGREEMENT THIS AGREEMENT made as of the 1st day of October, 2015. BETWEEN: CYNAPSUS THERAPEUTICS INC. (hereinafter called “Cynapsus”) - and - thierry bilbault (hereinafter called the “Executive”) WHEREAS Cynapsus is developing a sublingual thin filmstrip for the acute rescue of OFF motor symptoms of Parkinson’s disease; AND WHEREAS Cynapsus and the Executive entered into an |
|
| October 2, 2015 |
Cynapsus Therapeutics FORM 8-K (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 1, 2015 Cynapsus Therapeutics Inc. (Exact name of registrant as specified in its charter) Canada 001-37426 98-1226819 (State or other jurisdiction of incorporation) (Commissio |
|
| September 16, 2015 |
Cynapsus Therapeutics FORM 144 Form 144 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 OMB APPROVAL OMB Number: 3235-0101 Expires: May 7 2017 Estimated average burden hours per response 1.00 FORM 144 SEC USE ONLY NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933 DOCUMENT SEQUENCE NO. ATTENTION: Transmit for filing 3 copies of this form concurrently with either p |
|
| September 4, 2015 |
Cynapsus Therapeutics FORM 8-K (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 31, 2015 Cynapsus Therapeutics Inc. (Exact name of registrant as specified in its charter) Canada 001-37426 98-1226819 (State or other jurisdiction of incorporation) (Commissio |
|
| September 4, 2015 |
Director and Officer Indemnification Agreement Exhibit 10.1 Director and Officer Indemnification Agreement THIS INDEMNIFICATION AGREEMENT (the ?Agreement?) is made as of this 2nd day of September, 2015, between Cynapsus Therapeutics Inc. (the ?Corporation?), a corporation amalgamated under the Canada Business Corporations Act and (the ?Indemnified Party?). RECITALS: A. The Board of Directors of the Corporation (the ?Board?) has determined that |
|
| September 4, 2015 |
EX-10.2 3 v419702ex10-2.htm EXHIBIT 10.2 Exhibit 10.2 SHORT OCCUPANCY AGREEMENT THIS AGREEMENT made this 31th day of August, 2015. BETWEEN: Cynapsus Therapeutics., (The Tenant) A Company Incorporated under the laws of the Province of Ontario OF THE FIRST PART AND IMAGES LIFE MEDIA INC., (The Landlord) A Company Incorporated under the laws of the Province of Ontario OF THE SECOND PART The Tenant he |
|
| August 28, 2015 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Cynapsus Therapeutics Inc. (Name of Issuer) Common Shares, no par value (Title of Class of Securities) 23257Y859 (CUSIP Number) August 20, 2015 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rule pursuant to which thi |
|
| August 14, 2015 |
Cynapsus Therapeutics Reports Second Quarter 2015 Financial Results and Recent Developments EX-99.1 2 v418153ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Cynapsus Therapeutics Reports Second Quarter 2015 Financial Results and Recent Developments August 14, 2015 TORONTO – Cynapsus Therapeutics Inc. (NASDAQ: CYNA) (TSX: CTH) (“Cynapsus” or the “Company”), a specialty Central Nervous System (“CNS”) pharmaceutical company developing and preparing to commercialize a fast-acting, easy-to-use, sublingu |
|
| August 14, 2015 |
Cynapsus Therapeutics FORM 8-K (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 14, 2015 Cynapsus Therapeutics Inc. (Exact name of registrant as specified in its charter) Canada 001-37426 98-1226819 (State or other jurisdiction of incorporation) (Commissio |
|
| July 29, 2015 |
Exhibit 4.1 2014 AMENDED AND RESTATED STOCK OPTION PLAN CYNAPSUS THERAPEUTICS INC. (the ?Corporation?) DIRECTORS, MANAGEMENT, EMPLOYEES AND CONSULTANTS STOCK OPTION PLAN Article 1 - INTRODUCTION 1.1 Purpose The purpose of the Plan is to secure for the Corporation and its shareholders the benefits of incentives inherent in share ownership by the directors, management, employees and consultants of t |
|
| July 29, 2015 |
Cynapsus Therapeutics FORM S-8 S-8 1 v416180s-8.htm FORM S-8 As filed with the Securities and Exchange Commission on July 29, 2015 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 CYNAPSUS THERAPEUTICS INC. (Exact name of registrant as specified in its charter) Canada (State or other jurisdiction of incorporation or org |
|
| July 2, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| June 30, 2015 |
CYNA / Cynapsus Therapeutics Inc. / AISLING CAPITAL III LP - SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Cynapsus Therapeutics Inc. (Name of Issuer) Common Stock, no par value (Title of Class of Securities) 23257Y859 (CUSIP Number) June 23, 2015 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant t |
|
| June 23, 2015 |
Cynapsus Therapeutics 8-K (Current Report/Significant Event) 8-k SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported) June 23, 2015 CYNAPSUS THERAPEUTICS INC. (Exact name of registrant as specified in its charter) Canada 001-37426 Not Applicable (State or other jurisdiction of incorporation) (Commission File Nu |
|
| June 23, 2015 |
EX-99.1 Exhibit 99.1 Cynapsus Therapeutics Inc. Closes US$72.5 Million Public Offering of Common Shares in the United States Underwriters Exercise Option to Purchase Additional Common Shares in Full June 23, 2015 TORONTO, ONTARIO ? Cynapsus Therapeutics Inc. (NASDAQ: CYNA)(TSX: CTH) (the ?Company? or ?Cynapsus?) announced today that it has completed its previously announced underwritten public off |
|
| June 18, 2015 |
Cynapsus Therapeutics 8-K (Current Report/Significant Event) 8-k SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported) June 17, 2015 CYNAPSUS THERAPEUTICS INC. (Exact name of registrant as specified in its charter) Canada 001-37426 Not Applicable (State or other jurisdiction of incorporation) (Commission File Nu |
|
| June 18, 2015 |
SUPPL 1 d928636dsuppl.htm SUPPL Table of Contents Filed Pursuant to General Instruction II.L of Form F-10 File No. 333-204226 Information has been incorporated by reference in this prospectus from documents filed with the securities commissions or similar regulatory authorities in Canada. Copies of the documents incorporated by reference in this prospectus may be obtained upon request without char |
|
| June 18, 2015 |
EX-99.1 Exhibit 99.1 Cynapsus Therapeutics Inc. Announces Pricing of US$63.0 Million Public Offering of Common Shares in the United States TORONTO, ONTARIO?(Marketwired ? June 17, 2015) ? Cynapsus Therapeutics Inc. (TSX:CTH)(OTCQX:CYNAD) (the ?Company? or ?Cynapsus?) announced today the pricing of its underwritten public offering in the United States of 4,500,000 common shares at a price to the pu |
|
| June 18, 2015 |
Filed Pursuant to Rule 433 Issuer Free Writing Prospectus dated June 17, 2015 Relating to Preliminary Short Form Base PREP Prospectus dated June 9, 2015 Registration No. |
|
| June 17, 2015 |
F-10/A Table of Contents As filed with the Securities and Exchange Commission on June 17, 2015 Registration No. |
|
| June 12, 2015 |
8-A12B UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 CYNAPSUS THERAPEUTICS INC. (Exact name of registrant as specified in its charter) Canada Not Applicable (State of incorporation or organization) (I.R.S. Employer Identification No.) 28 Richm |
|
| June 9, 2015 |
F-10/A Table of Contents As filed with the Securities and Exchange Commission on June 9, 2015 Registration No. |
|
| May 15, 2015 |
F-X UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM F-X APPOINTMENT OF AGENT FOR SERVICE OF PROCESS AND UNDERTAKING A. Name of issuer or person filing (?Filer?): Cynapsus Therapeutics Inc. B. (1) This is x an original filing for the Filer. ? an amended filing for the Filer. (2) Check the following box if you are filing the Form F-X in paper in accordance with Regulatio |
|
| May 15, 2015 |
F-10 Table of Contents As filed with the Securities and Exchange Commission on May 15, 2015 Registration No. |
